New Alzheimer’s treatment approved: FQSA calls it a “hopeful step”… but urges caution

New Alzheimer’s treatment approved: FQSA calls it a “hopeful step”… but urges caution

The Fédération québécoise des Sociétés Alzheimer (FQSA) is reacting to Health Canada’s approval of Kisunla™ (donanemab), a new treatment intended for people in the early stages of Alzheimer’s disease.

Developed by Eli Lilly, the medication is part of a new generation of therapies that target amyloid plaques in the brain. According to clinical data, it may help slow cognitive decline in some patients, particularly when administered early in the progression of the disease.

The FQSA describes the approval as a hopeful development, while emphasizing that it is neither a cure nor a universal solution. The organization stresses that these therapies are intended for a very specific patient population and require strict medical supervision, including specialized testing.

Beyond the approval itself, the Federation highlights a key challenge: ensuring equitable access to the treatment across Quebec, especially in regional areas where specialized resources such as brain imaging and memory clinics are sometimes limited.

For the FQSA, this advancement also reinforces an important message: early diagnosis is more critical than ever, as these new treatments are most effective in the earliest stages of the disease.

The organization continues its awareness efforts to encourage the public to recognize early signs and seek medical advice promptly.